Skip to main content

Table 3 In vitro antifungal susceptibility testing of 201 clinical isolates into 5 antifungal agents

From: A seven-year surveillance study of the epidemiology, antifungal susceptibility, risk factors and mortality of candidaemia among paediatric and adult inpatients in a tertiary teaching hospital in China

Species
(No of isolates)
Antifungal agent Resistant n(%)e
Children (35) Adults(166) total Pc
Candida albicans(81) Amphotericin B 0 0 0b
Flucytosine 0 1(1.5) 1(1.2)b 0.618
Fluconazole 2(12.5) 17(26.2) 19(23.5) 0.248
Itraconazole 8(50.0) 22(33.8) 30(37.0)b 0.231
Voriconazole 4(25.0) 20(30.8) 24(29.6)b 0.651
Candida glabrata(73) Amphotericin B 1(5.6) 0 1(1.4)b 0.078
Flucytosine 0 0 0b
Fluconazole 1(5.6) 5(9.1) 6(8.2) 0.635
Itraconazole 2(11.1) 5(9.1) 7(9.6)b 0.801
Voriconazole 1(5.6) 2(3.6) 3(4.1)b 0.722
C.tropicalis(28) Amphotericin B 0 1(3.6) 1(3.6)b
Flucytosine 0 1(3.6) 1(3.6)b
Fluconazole 0 11(39.3) 11(39.3)b
Itraconazole 0 11(39.3) 11(39.3)b
Voriconazole 0 12(42.9) 12(42.9)b
C. krusei(6) Amphotericin B 0 0 0
Flucytosine 0 0 0
Fluconazolea
Itraconazole 0 1(16.7) 1(16.7)b
Voriconazole 0 1(16.7) 1(16.7)b
All of isolates (201) Amphotericin B 1(2.9) 1(0.6) 2(1.0) 0.222
Flucytosine 0(0) 2(1.2) 2(1..0) 0.513
Fluconazolea 3(8.6) 33(20.6) 36(18.5) 0.096
Itraconazole 10(28.6) 40(24.1) 50(24.9) 0.578
Voriconazole 5(14.3) 34(20.5) 39(19.4) 0.400
  1. MIC minimal inhibitory concentration
  2. aResistance rate was based on the intrinsic resistance of C. krusei and did not follow the actual MICs
  3. bThe breakpoints of Candida spp. according to the manufacturer’s instructions of ATB FUNGUS 3 system
  4. cThe difference of resistance rate between children and adults was analyzed by chi square test
  5. eC. parapsilosis and others isolates (C. guilliermondii (3), C. haemulonii (1) and C. inconspicua (1)) were susceptible to five antifungal agents (100%), so the results were not listed